The study's strongest evidence comes from rescue experiments: co-exposure with mevalonate or GGPP restored proliferation to 92β98% of control, while FPP only partially rescued (67%), pinpointing geranylgeranylationβnot farnesylationβas the critical mechanism . IC50 values (acid: 5β8 ΞΌg/mL; lactone: 7β9 ΞΌg/mL) are modestβ20 ΞΌM lovastatin/24h approaches clinically achievable exposures per an ovarian cancer parallel study .
2D-GE proteomics (n=4/group) identified 74 changed proteins in MDAMB231 and 42 in MDAMB468, validated by Western blot. Key hits: GDI-2 up (stabilizing inactive RhoA), membrane-bound RhoA down (acid > lactone), MCM7 to 28% of control, MSH2 down, prohibitin up, PTEN up/DJ-1 down/pAkt down/NDRG1 up . NMR metabonomics (n=3) showed dramatic metabolic collapse in MDAMB468:
Strengths: Dual orthogonal platforms (proteomics + NMR metabonomics) cross-validate; rescue experiments are mechanistically decisive; directionality is coherent across all three signaling axes.
Weaknesses: Only two ER-negative lines studiedβno ER-positive, normal breast, or in vivo validation. Metabonomics was performed only in MDAMB468, not in the more sensitive MDAMB231, creating a cell-line asymmetry in the integrated dataset . The 2D-GE platform has limited dynamic range and misses low-abundance and heavily modified proteins. The mechanistic link between DJ-1 regulation and pAkt suppression is explicitly speculativeβauthors call it a hypothesis requiring further evaluation. Findings in cardiomyocytes show lovastatin causes both mevalonate-dependent apoptosis AND mevalonate-independent oncosis , raising the possibility that some observed breast cancer effects also involve mevalonate-independent mechanisms the paper does not test. Additionally, later TNBC work found lovastatin IC50 of 7.97 ΞΌM (MDA-MB-231) consistent with this paper, but linked the effect to MNRR1 inhibitionβanother mechanism this 2010 study could not have detected .
What would change this conclusion: Failure of mevalonate/GGPP to rescue in a broader panel, absence of RhoA/GDI-2 changes on independent validation, or null in vivo xenograft results would falsify the central mechanism. No raw proteomics data deposition was described, limiting independent reanalysis.
Know what changed, what holds up, and what remains uncertain. Every Friday. No ads.